Millions of individuals in the United Kingdom rely on statins each year to manage their cholesterol levels, but groundbreaking research indicates that a simple change in prescribing rules could save thousands of lives annually. A comprehensive analysis has determined that patients with blocked arteries should immediately receive a combination of a statin and another medication called ezetimibe, rather than statins alone.
Significant Reductions in Mortality and Cardiovascular Events
The largest study to date examining the most effective method for lowering "bad" cholesterol in high-risk patients demonstrates that this combination therapy should be regarded as the "gold standard" of treatment. Researchers meticulously analysed data from 14 previous studies, encompassing 108,353 patients who were at "very high" risk of experiencing a heart attack or stroke, or who had already suffered such an event.
Published in the esteemed journal Mayo Clinic Proceedings, the findings reveal that when ezetimibe was combined with a high-dose statin to reduce low-density lipoprotein cholesterol (LDL-C) levels, there was a substantial 19% reduction in the risk of death from any cause. Additionally, deaths from cardiovascular causes decreased by 16%, and major adverse cardiovascular events or strokes were reduced by 18% and 17%, respectively, compared to high doses of statins alone.
Enhanced Cholesterol Control and Safety Profile
The combination therapy also achieved a significant extra reduction in LDL-C levels by 13mg per decilitre of blood compared to statin monotherapy, measured from the baseline when treatment commenced. This improvement increased the likelihood of patients reaching the ideal goal of less than 70mg/dL of LDL-C by an impressive 85%.
Study first author Professor Maciej Banach, from the John Paul II Catholic University of Lublin in Poland, elaborated on the results. "These outcomes were even more pronounced in the network meta-analysis, which allows for a direct comparison of different therapy regimens used in the study," he stated. "This showed a 49% reduction in all-cause mortality and a 39% reduction in major adverse cardiovascular events when compared to high-dose statin therapy alone."
Professor Banach, who also leads the International Lipid Expert Panel and the Blood Pressure Meta-analysis Collaboration group responsible for the study, emphasised the therapy's safety and efficacy. "The combination therapy is safe and efficacious. The risk of adverse events and the therapy discontinuation rate was comparable between groups. In the network meta-analysis, we demonstrated a significant 44% reduction in the risk of discontinuation in those treated with moderately high-dose statin therapy plus ezetimibe versus a high-dose statin alone."
Immediate Implementation as the Gold Standard
Historically, there have been inconsistent findings regarding whether combined cholesterol-lowering therapy should be administered immediately to high-risk patients, even before they suffer a heart attack or stroke. Study co-author Professor Peter Toth, from the University of Illinois in the United States, clarified this point. "This study confirms that combined cholesterol lowering therapy should be considered immediately and should be the gold standard for treatment of very high-risk patients after an acute cardiovascular event," he asserted.
Professor Toth further explained, "Simply adding ezetimibe to statin therapy, without waiting for at least two months to observe the effects of statin monotherapy—which is suboptimal in many patients—is associated with more effective LDL-C goal achievement and is responsible for significant incremental reductions in cardiovascular health problems and deaths. This approach does not require additional funding or reimbursement of new expensive drugs. In fact, it may translate into lower rates of first and subsequent heart attacks and strokes, and their complications like heart failure, which are extremely costly for all healthcare systems."
Global Impact and Recommendations
Statistics indicate that approximately 4.5 million deaths annually are attributable to high LDL-C levels. Professor Banach highlighted the broader context, noting, "Cardiovascular disease kills around 20 million people a year worldwide. Based on our previous analysis, we estimate that if combination therapy to reduce LDL-C was included in all treatment guidelines and implemented by doctors everywhere for patients with high cholesterol levels, it would prevent over 330,000 deaths a year among patients who have already suffered a heart attack, and almost 50,000 deaths alone in the USA."
He strongly recommended, "We advocate that combination therapy should be considered the gold standard of treatment for these patients and included in all future treatment guidelines."
Understanding the Medications
Statins have been safely utilised for years, functioning by lowering LDL-C "bad" cholesterol through reducing its production in the liver. Ezetimibe operates differently, diminishing the amount of cholesterol the body absorbs from food by inhibiting its absorption in the intestines. Some patients do not respond adequately to statins alone and are consequently prescribed ezetimibe in combination with a statin.
High doses of statins are classified as "high intensity," while moderately high doses are termed "moderate intensity" or "medium intensity" statins. Professor Toth concluded with a crucial insight, "Our findings underline the importance of the adages 'the lower for better for longer' but also the equally important 'the earlier the better' for treating patients at high risk of cardiovascular conditions and to avoid further medical complications and deaths."
